1. Scrip
  2. >>Business
  3. >>Deals

BMS Returns TIGIT Bispecific To Agenus Amid Pipeline Reshuffle

 
• By Alaric DeArment

Agenus said in an SEC filing that Bristol Myers Squibb was sending back AGEN1777, which entered into Phase II development earlier this year.

• Source: Shutterstock

Agenus Inc. said Bristol Myers Squibb Company returned rights to the TIGITxCD96-targeting bispecific antibody AGEN1777, the second piece of unwelcome news in less than a month for its immuno-oncology programs.

In a Securities and Exchange Commission filing on 2 August, Agenus said BMS had informed it that it would return AGEN1777 and terminate the three-year-old license agreement between the two companies for the product

Key Takeaways

  • In an SEC filing, Agenus said BMS had returned AGEN1777, which it had licensed in 2021 in a deal then worth potentially more than $1.5bn.

  • Agenus said the decision by BMS was part of a strategic realignment of its development pipeline

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Deals

AbbVie Pays $335m Up Front To Partner With ADARx On siRNA Therapeutics

 
• By Mandy Jackson

ADARx CEO Zhen Li told Scrip the collaborators will advance novel siRNA medicines, but ADARx retains its clinical-stage and many preclinical programs and remains open to more deals.

Bluebird, Private Equity Firms Look To Sweeten Buyout Deal

 
• By Alaric DeArment

Shareholders are being offered a flat fee of $5 per share as an alternative to $3 plus a contingent value right, which could be a more attractive option if they want cash up front.

Novo Nordisk Looks To Septerna For Oral Obesity Options

 
• By Mary Jo Laffler

Deal Snapshot: The Danish drugmaker is partnering with GPCR drug discovery expert Septerna to develop multiple small molecules for cardiometabolic targets.

GSK Pays $1.2bn For Phase III-Ready MASH Contender

 
• By Andrew McConaghie

The acquisition of Boston Pharma’s once-a-month FGF21 analog adds to GSK’s liver disease portfolio.

More from Business

Novo Nordisk Looks To Septerna For Oral Obesity Options

 
• By Mary Jo Laffler

Deal Snapshot: The Danish drugmaker is partnering with GPCR drug discovery expert Septerna to develop multiple small molecules for cardiometabolic targets.

AbbVie On MFN: ‘We Have To Take It Seriously’

 
• By Jessica Merrill

AbbVie chief commercial officer Jeffrey Stewart called Trump’s drug pricing plan a “disruption” but said ultimately the delta between US and EU drug prices may not be as high as some expect.

Industry Leaders Grapple With Trump’s MFN Pricing Plan

 
• By Jessica Merrill

At the Bank of America health care conference, pharma leaders speculated on what Trump’s executive order on drug pricing could mean for US and European drug prices.